OncBioMune Pharmaceuticals, Inc. announced the latest follow-up data from the Company’s Phase 1a trial of ProscaVax for prostate cancer. ProscaVax is OncBioMune's novel immunotherapeutic cancer vaccine consisting of a combination of prostate cancer associated prostate specific antigen (PSA) with the biological adjuvants interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF). In the trial, 20 hormone-naïve and hormone-independent recurrent prostate cancer patients with increasing PSA were treated with six intradermal injections of ProscaVax. The latest data shows: 14 of 20 (70%) patients have increased PSA Doubling Time (PSADT -the time for serum PSA to double its value and a key metric of disease progression) post-initiation of ProscaVax immunotherapy. This demonstrates a slowing of tumor growth at a minimum of 31 weeks post-initiation of ProscaVax immunotherapy. 15 of 18 patients have increased immunity to PSA at 31 weeks post-initiation of ProscaVax immunotherapy. Of the 20 patients that completed ProscaVax immunotherapy, 4 patients have shown disease progression at 31 weeks and one patient has chosen to withdraw from the study after week 19 without progression and entered another clinical trial. As a subset, of the four patients that demonstrated disease progression at 31 weeks, 3 did not have an increase in their PSADT.